




RealRate

PHARMACEUTICAL 2022

Albireo Pharma INC
Rank 252 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Albireo Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Albireo Pharma INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 39% points. The greatest weakness of Albireo Pharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 3.4% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	268,930
Cost of Goods Sold	1,356
Intangible Assets	17,260
Liabilities, Current	45,347
Liabilities, Non-Current	10,960
Other Assets	15,193
Other Compr. Net Income	9,717
Other Expenses	10,617
Other Liabilities	70,136
Other Net Income	89,455
Other Revenues	40,579
Property and Equipment	668
Research and Development	82,522
Selling, General and Administrative Expense	69,569

Output Variable	Value in 1000 USD
Assets	302,051
Liabilities	126,443
Expenses	164,064
Revenues	40,579
Stockholders Equity	175,608
Net Income	-34,030
Comprehensive Net Income	-29,172
BaseVar	366,154
ECR before LimitedLiability	165%
Economic Capital Ratio	278%